Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib + Cetuximab in Metastatic Colorectal Cancer
NCT00640471Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brivanib alaninate in metastatic colorectal cancer (mCRC), sponsored by Canadian Cancer Trials Group. Started May 2008; status: completed.
02
Drugs
brivanib alaninate
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00640471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640471.